Navigation Links
Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
Date:5/9/2013

RICHMOND, Calif., May 9, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier , Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 10:00 am PT on Thursday, May 16, 2013, at the Bank of America Merrill Lynch 2013 Health Care Conference which will be held in Las Vegas.  

(Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO)

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and  hemoglobinopathies such as beta-thalassemia and sickle cell anemia. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell f
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference
2. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
3. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
4. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
5. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
6. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
7. Sangamo BioSciences Announces Presentation at Seventh Annual JMP Securities Healthcare Conference
8. Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences
9. Sangamo BioSciences Reports First Quarter 2012 Financial Results
10. Sangamo BioSciences Announces First Quarter 2012 Conference Call and Webcast
11. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (PRWEB) January 15, 2014 Freeslate, ... solutions, today announced that Lupin Limited, one of India’s ... CM Protégé PharmD System for high throughput ... India, is focused on a wide range of quality, ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Carahsoft and ... Thursday, January 23, 2014 at 2pm EST (11am PST), ... The topic focuses on how technology can turn raw, ... decisions for government agencies. The online webinar will last ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of strategic ... business, and media events in the United States ... associate Virginia Cox , JD, is returning to the firm,s ... Cox re-joins 3D after more than two years of service ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2
... Ltd. (NYSE Amex:, SVA ), a leading developer and provider of ... and twelve month,periods ended December 31, 2008. , , ... 2008 sales increasing 39% year-over-year to $46.5, ... in 2008, up from 5.12 million in, ...
... Calif., April 9 Jivan announced today ... high-throughput transcriptome sequencing (RNA-Seq) and expression. Leveraging ... mRNA in biological samples, Jivan will provide ... will offer content for targeted sequencing with ...
... expansion of PROVENT(R) Sleep Apnea Therapy in Limited ... Inc. a privately-held, medical device company, focused on ... the appointment of John McCutcheon as President and ... company also announced that current CEO Jeffrey Nugent ...
Cached Biology Technology:Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 2Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 3Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 4Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 5Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 6Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 7Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 8Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 9Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 10Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 11Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 12Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results 13Jivan Focuses on Solutions for Transcriptome Sequencing 2Ventus Medical Appoints John McCutcheon as President and CEO 2
(Date:4/17/2014)... fish consumption advisories for expecting mothers are ineffective ... persistent organic pollutants (POPs). , The study, ... of Toronto Scarborough PhD student Matt Binnington and ... of environmental contamination, a mother,s compliance with advisories, ... influenced exposure in her children. , Their model ...
(Date:4/17/2014)... engineer has developed a patented technique that improves ... The same technique could help police during drug ... Kay L. Theede chair in engineering and department ... research team have created a template-based system that ... The distance detection method called stand-off bomb ...
(Date:4/17/2014)... honeybees in Europe, Asia and the United States are ... be impacting native honeybee populations at this time, according ... include including Nosema microsporidia and Varroa ... resilient to these invasive pests, which suggests to us ... Asia and the United States currently are not necessary ...
Breaking Biology News(10 mins):Fish consumption advisories fail to cover all types of contaminants 2Patented research remotely detects nitrogen-rich explosives 2East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3
... Harbor, N.Y. One way of regulating protein levels in ... These are intermediary molecules that are first copied from DNA ... then transported into the cell,s body to be translated into ... Spring Harbor Laboratory (CSHL) has now discovered that mRNAs can ...
... Without aggressive action to reduce soot emissions, the ... to be significantly accelerated in order to achieve international ... last December,s Copenhagen Accord, according to " Assessing the ... published online June 21 in the Proceedings of the ...
... the Danish Cancer Society and the Herlev University Hospital ... for multiple tumor markers in bladder cancer. The ... multiple short synthetic probes: application to methylation analysis of ... from patients with bladder cancer," appears in the July ...
Cached Biology News:Messenger RNAs are regulated in far more ways than previously appreciated, CSHL team finds 2Aggressive action to reduce soot emissions needed to meet climate change goals 2Aggressive action to reduce soot emissions needed to meet climate change goals 3New diagnostic test for bladder cancer 2
... Detection of the yolk protein Vtg in ... simple and sensitive biomarker for endocrine disrupting chemicals ... Vtg has become an accepted screening test for ... Vtg (rainbow trout) EIA kit is a double-antibody ...
... Laboratory (RTL) can provide you with ... ,,Microbial method development and validation ,Performance ... conditions of your GMP manufacturing environment ... offer a full spectrum of microbiological ...
... amino acid synthetic peptide whose sequence is from rat SCAMP 5. ... C - N(217) - Q - P - Q - ... - P - N - Y - T - Y - ... neutralization and control experiments with the polyclonal antibody that reacts with ...
... (gram quantities of IgY) , After we receive ... we segregate the appropriate number of chickens and ... eggs are collected (usually over a period of ... involves a total of four injections into the ...
Biology Products: